Prognostic Stage IV Breast Cancer AJCC v8 Withdrawn Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05093387SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast CancerTreatment